Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Net Margin (2016 - 2024)

Arcadia Biosciences' Net Margin history spans 11 years, with the latest figure at 2.22% for Q4 2024.

  • For Q4 2024, Net Margin rose 27719.0% year-over-year to 2.22%; the TTM value through Sep 2025 reached 0.52%, up 10510.0%, while the annual FY2024 figure was 53.93%, 12200.0% up from the prior year.
  • Net Margin reached 2.22% in Q4 2024 per RKDA's latest filing, up from 27.98% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 817.15% in Q1 2020 to a low of 3448.04% in Q2 2020.
  • Average Net Margin over 5 years is 273.68%, with a median of 48.96% recorded in 2022.
  • The largest YoY upside for Net Margin was 879943bps in 2020 against a maximum downside of -553523bps in 2020.
  • A 5-year view of Net Margin shows it stood at 244.37% in 2020, then plummeted by -191bps to 222.19% in 2021, then skyrocketed by 109bps to 19.75% in 2022, then tumbled by -1515bps to 279.41% in 2023, then surged by 99bps to 2.22% in 2024.
  • Per Business Quant, the three most recent readings for RKDA's Net Margin are 2.22% (Q4 2024), 27.98% (Q3 2024), and 60.41% (Q2 2024).